The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Casarett and Doull's Toxicology: The Basic Science of Poisons
(1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-5-448_2 · Cited by 3,302
Esters of Methanesulfonic Acid as Irreversible Inhibitors of Acetylcholinesterase
Kitz, R., & Wilson, I. B. (1962) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50153-8 · Cited by 1,519
Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.815 · Cited by 792
Lee, A. J., Cai, M. X., Thomas, P. E., Conney, A. H., & Zhu, B. T. (2003) · Endocrinology · doi:10.1210/en.2003-0192 · Cited by 456
Shitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407
Structure of Human Microsomal Cytochrome P450 2C8
Schoch, G. A., Yano, J. K., Wester, M. R., Griffin, K. J., Stout, C. D., & Johnson, E. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312516200 · Cited by 382
In Vitro Glucuronidation Using Human Liver Microsomes and The Pore-Forming Peptide Alamethicin
Fisher, M. B., Campanale, K., Ackermann, B. L., VandenBranden, M., & Wrighton, S. A. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15100-8 · Cited by 343
Gemfibrozil greatly increases plasma concentrations of cerivastatin
Backman, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 336
Niemi, M., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2003) · Diabetologia · doi:10.1007/s00125-003-1034-7 · Cited by 284
Database analyses for the prediction of in vivo drug–drug interactions from in vitro data
Ito, K., Brown, H. S., & Houston, J. B. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02041.x · Cited by 272
Leemann, T., Transon, C., & Dayer, P. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90285-b · Cited by 267
Effects of Freezing, Thawing, and Storing Human Liver Microsomes on Cytochrome P450 Activity
Pearce, R. E., McIntyre, C. J., Madan, A., Sanzgiri, U., Draper, A. J., Bullock, P. L., Cook, D. C., Burton, L. A., Latham, J., Nevins, C., et al. (1996) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.0294 · Cited by 253
Self-citationGemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes
Wang, J.-S., Neuvonen, M., Wen, X., Backman, J. T., & Neuvonen, P. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1352 · Cited by 189
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone
Niemi, M., Backman, J. T., Granfors, M., Laitila, J., Neuvonen, M., & Neuvonen, P. J. (2003) · Diabetologia · doi:10.1007/s00125-003-1181-x · Cited by 186
Zimmerman, H. J. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70097-0 · Cited by 186
Huang, S.-M. (2004) · Applications of Pharmacokinetic Principles in Drug Development · doi:10.1007/978-1-4419-9216-1_10 · Cited by 181
Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and Rifampicin
Kajosaari, L. I., Laitila, J., Neuvonen, P. J., & Backman, J. T. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_157.x · Cited by 172
Kumar, S., Samuel, K., Subramanian, R., Braun, M. P., Stearns, R. A., Chiu, S.-H. L., Evans, D. C., & Baillie, T. A. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.038992 · Cited by 166
Kitada, M., Kamataki, T., Itahashi, K., Rikihisa, T., & Kanakubo, Y. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)76460-6 · Cited by 162
Jones, D. R., Gorski, J. C., Hamman, M. A., Mayhew, B. S., Rider, S., & Hall, S. D. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35013-x · Cited by 145
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen, X., Wang, J. S., Backman, J. T., Kivistö, K. T., & Neuvonen, P. J. (2001) · PubMed · Cited by 139
Kanamitsu, S.-I., Ito, K., & Sugiyama, Y. (2000) · Pharmaceutical Research · doi:10.1023/a:1007509324428 · Cited by 130
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone
Jaakkola, T., Backman, J. T., Neuvonen, M., & Neuvonen, P. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.12.266 · Cited by 119
In Vitro Inhibition and Induction of Human Hepatic Cytochrome P450 Enzymes by Modafinil
Robertson, P., DeCory, H. H., Madan, A., & Parkinson, A. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15146-x · Cited by 116
Self-citationLü, P., Schrag, M. L., Slaughter, D. E., Raab, C. E., Shou, M., & Rodrigues, A. D. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1352 · Cited by 109
Self-citationDisposition and Chemical Stability of Telmisartan 1-O-Acylglucuronide
Ebner, T., Heinzel, G., Prox, A., Beschke, K., & Wachsmuth, H. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15038-6 · Cited by 98
Comparative Effects of Fibrates on Drug Metabolizing Enzymes in Human Hepatocytes
Prueksaritanont, T., Richards, K. M., Qiu, Y., Strong-Basalyga, K., Miller, A. R., Li, C., Eisenhandler, R., & Carlini, E. J. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9011-5 · Cited by 73
Ingelman‐Sundberg, M., Rane, A., & Gustafsson, J. A. (1975) · Biochemistry · doi:10.1021/bi00673a033 · Cited by 50
Ryan, D. E., Dixon, R., Evans, R. H., Ramanathan, L., Thomas, P. E., Wood, A. W., & Levin, W. (1984) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(84)90489-2 · Cited by 50
Melet, A., Marques‐Soares, C., Schoch, G., Macherey, A., Jaouen, M., Dansette, P. M., Sari, M., Johnson, E. F., & Mansuy, D. (2004) · Biochemistry · doi:10.1021/bi0489309 · Cited by 49
Lilja, J. J., Backman, J. T., & Neuvonen, P. J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02323.x · Cited by 45
Niemi, M., Backman, J. T., Juntti‐Patinen, L., Neuvonen, M., & Neuvonen, P. J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02385.x · Cited by 43
Ohmori, S., Fujiki, N., Nakasa, H., Nakamura, H., Ishii, I., Itahashi, K., & Kitada, M. (1998) · PubMed · Cited by 27
INTERACTION BETWEEN FIBRATES AND STATINS - METABOLIC INTERACTIONS WITH GEMFIBROZIL
Fujino, H., Yamada, I., Shimada, S., Hirano, M., Tsunenari, Y., & Kojima, J. (2003) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2003.19.3.161 · Cited by 23
Drug-Drug Interactions Involving the Membrane Transport Process
Rodrigues, A. D. (2001) · CRC Press eBooks · doi:10.1201/b14003-8 · Cited by 14
Self-citation
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Impact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 633
Metadata
- Authors
- Ogilvie, B. W., Zhang, D., Li, W., Rodrigues, A. D., Gipson, A. E., Holsapple, J., Toren, P., & Parkinson, A.
- Venue
- Drug Metabolism and Disposition
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 34
- Issue
- 1
- Pages
- 191-197
- ISSN
- 0090-9556 (ISSN-L)
- OpenAlex
- W2132733182
- Cited by
- 330
- References
- 35
- FWCI
- 16.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.